Skip to content
Open access

Potent halt of SARS-CoV-2 replication using clitocine-induced emergent-viral-RNA editing and disruption

Sep 2026 · RSC Advances · 0 citations · 35 references
Medicine

TL;DR

The in vitro anti-RdRp, anti-ExoN, and anti-SARS-CoV-2 assays demonstrated the potent inhibitory activities of the CLT molecule and its expected major active metabolite, CLT triphosphate (CLT-TP), on coronaviral replication, with very interesting 50% inhibitory concentration values against the nirmatrelvir-resistant SARS-CoV-2 variant “NRSV”.

Abstract

Potently inhibiting the functions of the replication proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or inducing erroneous editing of newly replicated SARS-CoV-2 RNA strands during replication, is among the most effective anti-SARS-CoV-2 approaches. Nucleosides and their phosphorylated derivatives (i.e., nucleotides) are considered ideal options for stopping various infections of coronavirus disease 2019 (COVID-19). Clitocine (CLT) is a phosphorylatable natural nucleoside analog that is isolated mainly from two edible mushrooms, Clitocybe inversa and Leucopaxillus giganteus, and it is uniquely characterized by a nitro group on its pyrimidine ring. CLT and many of its derivatives are well known mainly for their potent anticancer activities. Leveraging the use of its favorable and rare chemical structure in medicinal chemistry and drug development, herein, we biochemically evaluated and computationally explained the potential capacity of CLT to mutate and disable the emergent viral RNA strands during the coronaviral replication processes against the SARS-CoV-2 particle and two of its essential replication proteins, the RNA-dependent RNA polymerase (RdRp) and 3′-to-5′ exoribonuclease (ExoN) enzymes, which are crucial for a complete and functioning replication machinery. The in vitro anti-RdRp, anti-ExoN, and anti-SARS-CoV-2 assays demonstrated the potent inhibitory activities of the CLT molecule and its expected major active metabolite, CLT triphosphate (CLT-TP), on coronaviral replication, with very interesting 50% inhibitory concentration (IC50) values against the nirmatrelvir-resistant SARS-CoV-2 variant “NRSV” (0.19, 0.20, and 0.38 µM for CLT and 0.15, 0.18, and 0.34 µM for CLT-TP, respectively), using the structurally similar and approved anti-SARS-CoV-2 medication molnupiravir (MNP) and its known active triphosphate metabolite, β-D-N4-hydroxycytidine 5′-triphosphate (NHC-TP), respectively, as reference drugs. The subsequent in silico simulations and computations, by implementing mainly the relevant molecular docking and molecular dynamics (MD) simulations, adequately expounded these biochemical findings. Through this new study, we also succeeded in uncovering and explaining the molecular-level mechanistic hallmarks of CLT/CLT-TP with respect to disrupting and impairing the coronaviral replication, as well as militating COVID-19 in a comprehensive way. In conclusion, the presented results need to be further confirmed by robust preclinical and clinical studies, along with the use of CLT as a promising pioneering parent anti-SARS-CoV-2 nucleoside analog by medicinal chemists for the synthesis of a wide spectrum of anti-RdRp nitronucleoside derivatives with ExoN-resistant chain-terminating activities (i.e., with ExoN-proofreading-escaping capacities) for optimum activity against coronaviruses.

Read PDF

Similar papers

Open access Sep 2026

Non‑nucleoside inhibitors of SARS‑CoV‑2 RdRp identified by high‑throughput screening and an approach to their mechanism of action by comparative studies

The findings expand the repertoire of NNIs against SARS-CoV-2 RdRp, establish a unified framework for comparative evaluation of RdRp inhibitors, and provide insights into the differential impacts of the NNIs on RdRp-RNA complex formation, thereby supporting future development of allosteric antiviral therapeutics.

Shang-Qian Wu, Chu-Wei Yang, Dong-Ying Li et al. · 0 citations

A Versatile Single-Round SARS-CoV-2 System for Interrogating Antivirals and Host Determinants

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) highlighted the need for experimental systems that enable investigation of viral replication, assembly, and host-virus interactions while minimizing the biosafety constraints associated with infectious virus. Although authentic SARS-CoV-2 remains the gold sta...

Su-Duo Jiang · 0 citations
Open access Sep 2026

The nucleoside analog CMX521 inhibits coronavirus RNA-dependent RNA polymerase via a two-pronged mechanism

These findings establish a two-pronged mode of coronavirus polymerase inhibition by CMX521, and suggest a second inhibitory mechanism for CMX521 when the coronavirus polymerase is associated with the viral helicase.

Asif Rakib, Calvin J. Gordon, Thomas K. Anderson et al. · 0 citations
Review Open access Sep 2026

SARS-CoV-2 Drug-Resistant Mutations in Non-Structural Proteins

Evaluating the drug resistance mechanisms of multiple SARS-CoV-2 non-structural proteins, including the main protease and the RNA-dependent RNA polymerase, as well as PLPro, EndoU, and Mac1, which contribute to viral replication and counter host innate immune responses are discussed.

M. Shaw, A. Fehr · 0 citations
#protein folding Open access Aug 2026

Scarless SARS-CoV-2 Genome Engineering and Variant Analysis

A genome engineering technology is used to change a single amino acid in the viruses’ main protease enzyme to match that of circulating Omicron isolates to demonstrate antiviral efficacy of approved drugs and uncover mutants with reduced drug sensitivity.

Agnieszka Dabrowska, Ashley Cuell, Rahul Basu et al. · 0 citations
Sep 2026

In-silico Analysis of 1,3,4-Thiadiazol-2-yl) benzenesulfonamide Targeting SARS-CoV-2 Spike Glycoprotein and Papain-like Protease.

BACKGROUND The COVID-19 pandemic, caused by the SARS-CoV-2 virus, results in severe acute respiratory illness and has been declared a global public health emergency. Developing effective therapeutic strategies to control the infection remains an urgent priority. The viral spike glycoproteins and proteases play crucial...

Aakrshit Singh, Gaurav Krishna, Shilpi Sonker et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.